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Abstract
The CKD-associated decline in soluble α-Klotho levels is considered detrimental. Some in
vitro and in vivo animal studies have shown that anti-oxidant therapy can upregulate the
expression of α-Klotho in the kidney. We examined the effect of anti-oxidant therapy on α-
Klotho concentrations in a clinical cohort with mild tot moderate chronic kidney disease
(CKD). We performed a post-hoc analysis of a prospective randomized trial involving 62
patients with mild to moderate CKD (the ATIC study), all using an angiotensin-converting
enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) for 12 months. On top of
that, the intervention group received anti-oxidative therapy consisting of the combination of
pravastatin (40 mg/d) and vitamin E (α-tocopherol acetate, 300 mg/d) while the placebo
was not treated with anti-oxidants. α-Klotho concentrations were measured at baseline and
after 12 months of anti-oxidant therapy. Data were analysed using T-tests and Generalized
Estimating Equations, adjusting for potential confounders such as vitamin D, parathyroid
hormone, fibroblast-growth-factor 23 (FGF23) and eGFR. The cohort existed of 62 patients
with an eGFR (MDRD) of 35 ± 14 ml/min/1.72m2, 34 were male and mean age was 53.0 ±
12.5 years old. Anti-oxidative therapy did successfully reduce oxLDL and LDL concentra-
tions (P <0.001). α-Klotho concentrations did not change in patients receiving either anti-
oxidative therapy (476.9 ± 124.3 to 492.7 ± 126.3 pg/mL, P = 0.23) nor in those receiving
placebo 483.2 ± 142.5 to 489.6 ± 120.3 pg/mL, P = 0.62). Changes in α-Klotho concentra-
tions were not different between both groups (p = 0.62). No evidence was found that anti-
oxidative therapy affected α-Klotho concentrations in patients with mild-moderate CKD.
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Introduction
Prevention and better treatment of cardiovascular (CV) disease in CKD is one of the main
challenges in current nephrology. Despite successful interventions on traditional risk factors
such as blood pressure, dyslipidaemia and proteinuria, CV risk in CKD remains excessively
high [1]. A rapidly increasing body of evidence supports involvement of the fibroblast growth
factor 23 (FGF23)-klotho-vitamin D axis in the pathogenesis of cardiovascular disease in CKD
patients [2]. Therapeutic reduction of oxidative stress in patients with CKD, for instance with
HMG-CoA reductase inhibitors, could improve CV outcome [3]. However, whether antioxi-
dant therapy induces favorable changes in the FGF23-Klotho-vitamin D axis and thereby
improvements in CV outcome is unknown.
The α-Klotho gene was discovered in 1997 as an anti-aging gene [4]. α-Klotho is predomi-
nantly produced in the kidneys [5]. α-Klotho expression is downregulated by CKD-associated
uremic toxins and oxidative stress and enhanced activity of the renin-angiotensin-aldosterone
system (RAAS) [6–8]. A vicious circle could ensue, because vitamin D deficiency increases
renin and subsequently angiotensin II, which is known to suppress α-Klotho and leads to sub-
sequent high FGF23 concentrations, which in turn suppress vitamin D activation[9]. Lower α-
Klotho concentrations are associated with progressive CKD[10], higher prevalence of cardio-
vascular disease[11], arterial stiffness [12], vascular calcification[13].
Therefore, increasing α-Klotho could be a legitimate goal in CKD patients. Several recent
studies assessed different experimental options to up-regulate endogenous α-Klotho [7,9,14–
24] through therapeutic reduction of oxidative stress with the administration of anti-oxidants
[9,21,22] and HMG-CoA reductase inhibitors [23,24] However, whether anti-oxidant therapy
increases α-Klotho in patients is unknown.
We hypothesized that a 12-month anti-oxidant therapy compared to placebo, induces an
increase of α-Klotho. Therefore, in this study we measured α-Klotho before and after treatment
with anti-oxidative therapy (vitamin E combined with a statin) or placebo in patients with




For the current analysis we performed a post-hoc analysis on subjects from the prospective
randomised ATIC trial of whom blood and urine samples were available (25). Originally in this
study 93 subjects with mild-moderate CKD (creatinine clearance of 15–70 mL/min/1.73m2
according to the Cockroft-Gault equation), on background treatment of inhibition of the
renin-angiotensin system (RAS) by either angiotensin receptor blockers (ARB) or angiotensin
converting enzyme (ACE)-inhibition were randomised to either a anti-oxidant regime com-
prising of pravastatin (40 mg/d) starting at baseline followed by the addition of vitamin E (α-
tocopherol acetate, 300 mg/d) at month 6, or placebo for 12 months. Endpoints of the original
study were common carotid intima-media thickness, brachial artery flow-mediated dilatation,
albuminuria and renal function (eGFR). Details and results of the study have been published
previously [25]. Excluded were subjects with diabetes, active vasculitis, nephrotic syndrome,
renal transplantation, a fasting cholesterol level higher than 270 mg/dL (7.00 mmol/L), choles-
terol-lowering therapy within 3 months prior to inclusion, or ischemic coronary, cerebrovascu-
lar, or peripheral arterial disease. The patients included in the ATIC study already provided
informed consent for their samples to be stored and used in the future for research purposes
without any further asking.
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Data collection
Of the 93 patients from the ATIC study, complete serum samples were available from 62
patients, which formed the base of the current analysis. The following data were recorded: age,
gender, body mass index, smoker or non-smoker, renal function as determined by eGFR
(MDRD) and serum creatinine (μmol/L). Plasma-oxidized low-density lipoprotein (oxLDL)
and malondialdehyde were measured as quantitative indicators of oxidative stress. α-Klotho
and vitamin D (25(OH)D) and phosphate concentrations were measured in serum samples
and parathyroid hormone (PTH) and c-terminal fibroblast-growth-factor-23 (cFGF23) con-
centrations in plasma samples, all at baseline and after 12 months of treatment. The α-Klotho
immunoassay (IBL international GmbH, Hamburg, Germany) was used to measure α-Klotho
[26] with an intra-assay variation of<5% and an inter assay variation< 7.5%; c-terminal
FGF23 was measured in EDTA-plasma using ELISA (Immutopics) [27]with an intra-assay var-
iation of<5% and an inter assay variation< 10%. 25(OH)D was measured using the radioim-
munoassay (Diasorin) (intra-assay variation of<10% above a concentration of 25 nmol/L and
inter assay variation< 11% above a concentration of 25 nmol/L) and PTH using an automated
immunoassay (Architect Abbott Diagnostics) (both intra- and inter assay variation<5% above
a concentration of 1 pmol/L). Creatinine and phosphate were measured in 24-hour urine sam-
ples. All assays were run in the year 2013.
Statistical analysis
Continuous variables are given as mean ± standard deviation for normally distributed data or
as median [interquartile range] for skewed data. Categorical variables are given as number of
patients and percentages. Normally distributed numerical variables were compared using an
unpaired T-test, otherwise Mann-Whitney U test was used; categorical variables were com-
pared by Chi-square test. Changes within the two treatment groups of oxLDL, LDL, MDA,
eGFR and cFGF23 were analysed using paired T-test; between group differences were analysed
using an unpaired T-test on deltas (Δ). In order to adjust the effects of the two treatment strate-
gies on α-Klotho for confounders, General Estimating Equations, a regression technique suit-
able for longitudinal data analysis, was used. In the model with α-Klotho as dependent variable
and treatment as determinant, vitamin D, parathyroid hormone, cFGF23 and renal function
were added as confounders. In addition, to evaluate effect modification of the intervention, the
product of time and group (timegroup) was added as an independent variable in these analy-
sis. A non-parametric correlation analysis was made between α-Klotho levels and FGF23 using
Spearman’s rho. P-values< 0.05 were considered statistically significant. All analyses were per-
formed using IBM SPSS Statistics software version 20. Details of statistical analysis are available
in the S1 File.
Results
Characteristics of the study population
Data were analysed from 62 patients, 34 patients in the anti-oxidant intervention group, 28 in
placebo group. In our cohort were fewer men than woman but otherwise it is a representative
reflection of the original ATIC cohort. The mean age of the participants was 53 years old
(range from 20–79 years old) and all patients suffered from chronic kidney disease stage 3–4
(eGFR 15–60 mL/min/1.73 m2)[28]. At baseline, there were no important differences in demo-
graphic and clinical parameters between both arms, as shown in Tables 1 and 2. Full data set
available in the S2 File.
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Markers of oxidative stress. After 12 months, there was a statistically significant reduction
of oxLDL (from 66.8 U/L ± 13.3 to 55.2 U/L ± 12.9, P<0.001) and low-density lipoprotein cho-
lesterol (from 3.8 ± 0.93 mmol/L to 2.6 ± 0.71mmol/L, P<0.001) levels within the intervention
group. There was no reduction of plasma malondialdehyde (from 7.7 ± 1.3 μmol/L to
7.8 ± 1.1 μmol/L, P = 0.38) during the study period. Levels of oxLDL, low-density lipoprotein
cholesterol and plasma malondialdehyde all increased in the placebo group (from 60.2 U/
L ± 15.5 to 63.4 U/L ± 16.7, from 3.2 ± 0.8 mmol/L to 3.4 ± 0.8 mmol/L, and from
7.7 ± 1.3 μmol/L to 8.0 ± 1.2 μmol/L resp.). However, this increase was only significant in the
oxLDL levels (see Table 2).
Renal function and cFGF23
After 12 months, the mean eGFR had decreased from 33 ± 13 mL/min/1.73m2 to 32 ± 14 mL/
min/1.73m2 in the intervention group (P = 0.10) and decreased from 38 ± 15 mL/min/1.73m2 to
37 ± 16 mL/min/1.73m2 in the placebo group (P = 0.30) (P = 0.60 for between-group difference).
The median of cFGF23 changed from 181.0 RU/mL (IQR: 130.0–310.5) to 179.0 RU/mL
(137.8–318.0) in the intervention group (P = 0.14). In the placebo group the median of cFGF23
changed from 150.0 (90.8–236.8) RU/mL to 145.0 (IQR: 95.0–359.0) RU/mL (P = 0.001) (P for
between-group difference = 0.33).
Table 1. Baseline characteristics of participants.
Placebo group (n = 28) Intervention group (n = 34)
Age (years) 51 ± 15 54 ± 11
Male, no. (%) 18 (64.3) 16 (47.1)
BMI (kg/m2) 25.9 ± 4.0 26.5 ± 4.9
Smokers, no. (%) 12 (52.2) 11 (47.8)
eGFR (ml/min/1.73m2) 38 (15) 33 (13)
25(OH)D (nmol/L) 70.2 ± 31.0 66.9 ± 32.5
PTH (pmol/L) (median + IQR) 8.9 (5.2–13.1) 8.6 (4.9–13.0)
Values are expressed as mean ±SD, unless speciﬁed otherwise. IQR = interquartile range
doi:10.1371/journal.pone.0144121.t001
Table 2. Time-related results within and between groups. Values are expressed as mean with 95% confidence interval (95%CI).
PLACEBO (n = 28) INTERVENTION (n = 34) p for between-group
difference
Baseline After 12 months of
treatment
Baseline After 12 months of
treatment
Mean (95%CI) Mean (95%CI) p Mean (95%CI) Mean (95%CI) p
Phosphate (mmol/L) 1.19 (1.11–1.28) 1.29 (1.19–1.40) 0.01 1.27 (1.14–1.39) 1.35 (1.18–1.51) 0.26 0.07
oxLDL (U/L) 60.2 (53.9–66.5) 63.4 (56.6–70.1) 0.03 66.8 (62.1–71.4) 55.1 (62.1–71.4) <0.001 <0.001
LDL (mmol/L) 3.2 (2.9–3.6) 3.4 (3.0–3.7) 0.22 3.8 (3.5–4.2) 2.6 (2.3–2.9) <0.001 <0.001
MDA (μmol/L) 7.7 (7.1–8.2) 8.0 (7.6–8.5) 0.10 7.7 (7.2–8.1) 7.8 (7.4–8.2) 0.38 0.37
eGFR (mL/min/1.73m2) 38 (32–43) 37 (31–43) 0.30 33 (29–38) 32 (27–37) 0.10 0.60
cFGF23* (RU/mL) 150.0 (90.8–
236.8)
145.0 (95.0–359.0) 0.001 181.0 (130.0–
310.5)
179.0 (137.8–318.0) 0.14 0.33
α-Klotho (pg/mL) 483.2 (427.9–
538.5)
489.6 (443.0–536.3) 0.62 476.9 (433.6–
520.3)
492.7 (448.6–536.7) 0.23 0.62
Urinary phosphate
(mmol/L)
12.3 (10.0–14.6) 12.4 (9.8–15.0) 0.97 11.6 (8.8–14.4) 9.3 (7.7–11.0) 0.02 0.32
* cFGF23 is expressed as median and interquartile range.
doi:10.1371/journal.pone.0144121.t002
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Effect of anti-oxidative therapy on circulating Klotho concentrations
α-Klotho concentrations at baseline increased from mean 476.9 ± 124.3 pg/mL to mean
492.7 ± 126.3 pg/mL for the intervention group (P = 0.23). In the placebo group α-Klotho con-
centrations increased from mean 483.2 ± 142.5 pg/mL to mean 489.6 ± 120.3 pg/mL
(P = 0.62). The interaction term showed that α-Klotho levels did not significantly change over
time in the intervention group compared to the placebo group (P = 0.62, Fig 1, and model 2,
Table 3). Adjusting for the potential confounders eGFR, cFGF23, PTH and 25 hydroxyvitamin
D3 did not influence results between the groups (p = 0.89, model 3 in Table 3).
We found no correlation between α-Klotho concentrations and cFGF23 levels (Spearman
correlation coefficient = -0.045, p = 0.73).
Fig 1. The effect of anti-oxidative therapy on α-Klotho concentrations.Data shown are means with 95%
confidence interval.
doi:10.1371/journal.pone.0144121.g001
Table 3. The effect of anti-oxidant treatment on α-Klotho in a multivariable GEE analysis.
Intervention versus placebo (change in pg/ml α-Klotho) β (95% CI)
Crude -1.6 (-62.5–59.3)
Model 11 8.4 (-53.8–70.6)
Model 22 3.6 (-62.8–70.0)
Model 33 8.9 (-71.5–89.4)
1 Model 1: Adjusted for time course, MDRD
2 Model 2: Adjusted for variables from Model 1, plus an interaction term between group and time
3 Model 3: Adjusted for all variables from Model 2 plus 25OH-vitamin D, cFGF23, PTH, phosphate, calcium
doi:10.1371/journal.pone.0144121.t003
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Discussion
This study demonstrates that there is no effect of the combined treatment with pravastatin and
vitamin E as anti-oxidative therapy on α-Klotho concentrations in patients with mild-moder-
ate CKD, despite that efficacy of anti-oxidative therapy to reduce oxidative stress was demon-
strated by a decline of oxLDL concentrations.
Our data contradict experimental in vitro and in vivo animal studies that showed decreased
Klotho expression in the kidney following oxidative stress. Subsequent administration of a free
radical scavenger prevented this Klotho downregulation by oxidative stress [7,9,21,22,29–31].
The lack of an increase in α-Klotho concentrations under clinical anti-oxidative therapy in our
study could have several explanations. First of all, we measured circulating α-Klotho concen-
trations; most of the previous in vitro and in vivo animal studies measured renal membrane
bound Klotho. Second, we do not know if the anti-oxidative therapy patients received in this
study was of sufficient potency to induce an upregulation of α-Klotho. Although the decline in
oxLDL was statistically significant, we cannot exclude that more pronounced attenuation of
oxidative stress would have resulted in higher concentrations of α-Klotho. However, Tamura
et al. treated hypercholesterolemic patients during 8 weeks with a lower dose pravastatin than
in our study (10 mg/day vs 40 mg/day) and they showed a significant reduction in plasma mal-
ondialdehyde with 14±13% [32]. Administration of rosuvastatin 20mg/day reduced both
oxLDL and malondialdehyde levels in patients with atherosclerotic cerebrovascular disease
[33]. Supplementation of vitamin E also has shown to decrease oxidative stress in an earlier
study in patients with end-stage kidney disease [34]. We were not informed about therapy
compliance of the patients in the ATIC study. However, given the response in both LDL cho-
lesterol and oxLDL this is an unlikely explanation for the lack of effects on α-Klotho.
Even more, the patients in this study all used an ACEi or ARB from at least 2 weeks before
baseline. Karalliedde et al. showed that treatment with valsartan, an ARB, is associated with an
increase in sKlotho levels in patients with type 2 diabetes, systolic hypertension and albumin-
uria [35]. It is therefore conceivable that an previous increment of α-Klotho concentrations
induced by inhibitors of the RAS prevented a subsequent further rise by our anti-oxidant strat-
egy. The patients in our study had indeed higher baseline concentrations of α-Klotho when
compared to the α-Klotho concentrations in patients with CKD stage 3 and 4 mentioned in the
study of Kim et al. (10)
No data on α-tocopherol concentrations are available for our study, therefore we cannot
exclude that α-tocopherol concentrations were sufficient at baseline, limiting an effect of anti-
oxidative therapy on α-Klotho concentrations.
There are some limitations to this study that need to be acknowledged. The sample size of
62 patients is relatively small, leaving the possibility of a type II error. This also limited the abil-
ity to correct for confounding. However, a statistically significant difference in oxidative stress,
as measured by oxLDL, was found between the two treatment arms, implicating that a differ-
ence in α-Klotho would had been detected in case oxidative stress had been an important fac-
tor. We cannot rule out however that the magnitude of reduction in oxidative stress was
insufficient to influence α-Klotho concentrations. In the original ATIC study however, the
multistep intervention was sufficient to modulate common carotid intima media thickness,
albuminuria and brachial artery flow-mediated dilation. In addition to the potential of a type II
error, small sample size in general limits the external validity of our findings. Another potential
weakness, as mentioned, is that all patients were using either ARB or ACE-inhibitors, which
may have induced an unnoticed, increase in α-Klotho, and precluded a further increment.
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Finally, the IBL-assay used to measure α-Klotho concentrations has also some shortcom-
ings. It is uncertain if and which forms of α-Klotho are detected and a cross reactivity with
other solutes cannot be excluded [26,36].
The strengths of this study are the prospectively collected data with a randomised design,
and the attained contrast between treatment groups in terms of biochemical indices of oxida-
tive stress.
In conclusion, this study could not confirm our hypothesis that anti-oxidative therapy with
pravastatin and vitamin E increases α-Klotho concentrations in patients with mild-moderate
CKD on background therapy with ACE-inhibitors. Further research on this topic is warranted.
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